BD‐2 is a biomarker of IL‐17A‐driven pathology in psoriasis and S100A7 is associated with the severity of HS disease (Hurley staging), making these mediators useful surrogate markers of downstream IL‐17 activity.41 Here, IL17A is linked to psoriasis.